Status:
UNKNOWN
The Exploratory Study on the Nicotinamide Mononucleotide (Vital NAD ) to Promote the Rejuvenation of the Peripheral Blood Immune Cells of Adults.
Lead Sponsor:
Shanghai Cell Therapy Group Co.,Ltd
Collaborating Sponsors:
Shanghai Mengchao Cancer Hospital
Conditions:
Enhance Immune Function
Eligibility:
All Genders
18-80 years
Phase:
EARLY_PHASE1
Brief Summary
The purpose of this study is to investigate the changes in adult peripheral blood immune cell subpopulations, subpopulations, and cell functional status before and after intervention with Nicotinamide...
Detailed Description
This study focuses on the effects of Nicotinamide mononucleotide (Vital NAD) as NAD+ supplement on the subtypes and biological functions of immune cells of Adults, especially the types and subsets of ...
Eligibility Criteria
Inclusion
- Male/females of 18 to 80 years of age.
- Able to provide written Informed Consent.
- BMI 25.0-44.9 kg/m².
- Able to follow verbal and written study directions.
- Must not be taking or be willing to take any supplements containing any form of niacin for seven days prior to baseline and for the duration of the study.
- Able to maintain consistent diet and lifestyle habits according to the study.
Exclusion
- 1\. Diabetes.
- Premenopausal or menopause \<1 year.
- Persons who have received hormone replacement therapy within the past 6 months.
- Persons who take vitamin B supplementation and are not willing to discontinue supplementation for 3 weeks before and during the entire study period.
- Unstable weight (\>3% change during the last 2 months before entering the study).
- Significant organ system dysfunction or disease.
- Present cancer or history of cancer that has been in remission for \<5 years.
- Polycystic ovary syndrome.
- Major psychiatric illness.
- Use of medications known to affect study outcome measures (e.g., steroid) or increase the risk of study procedures (e.g., anticoagulants) that cannot be temporarily discontinued for the study.
- Metal implants.
- Persons who consume \>14 units of alcohol per week.
- Unable or unwilling to follow the study protocol or who, for any reason, is considered an inappropriate candidate for the study by the research team.
Key Trial Info
Start Date :
August 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2024
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT05984550
Start Date
August 1 2023
End Date
December 1 2024
Last Update
August 21 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shanghai Mengchao Cancer Hospital
Shanghai, China